William E Gillanders MD
Breast, Endocrine, Surgical Oncology (Other than Breast)
Professor, Surgery, Washington University School of Medicine
Join to View Full Profile
4500 Forest Park AveDiv Surg Oncology 5TH FLSt. Louis, MO 63108
Phone+1 314-362-2280
Fax+1 888-352-8360
Dr. Gillanders is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Surgery, 1991 - 1999
Duke University School of MedicineClass of 1991
Certifications & Licensure
MO State Medical License 2005 - 2027
SC State Medical License 1999 - 2005
American Board of Surgery Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Follow My Health, Jardogs, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification Allscripts Enterprise EHR, Allscripts, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012, 2014-2017
Clinical Trials
- Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14
- A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients Start of enrollment: 2005 Nov 01
- LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- Deviating from Thyroid Imaging Reporting and Data Systems (TI-RADS) guidelines in surgical planning for patients with parathyroid disease: What is the clinical impact?Shaleen V Sathe, Abigail Chmiel, Caroline Jones, William E Gillanders, John A Olson Jr
Surgery. 2026-01-01 - ImmunoNX: a robust bioinformatics workflow to support personalized neoantigen vaccine trials.Kartik Singhal, Evelyn Schmidt, Susanna Kiwala, S Peter Goedegebuure, Christopher A Miller
Arxiv. 2025-12-09 - Long-Acting Recombinant IL-7 (rhIL-7-hyFc) Enhances the Primary and Memory Neoantigen-Specific Immune Response to Breast Cancer Personalized Cancer Vaccines.Michael Chen, Thomas Kane, Ina Chen, Suangson Supabphol, Xiuli Zhang
Cancers. 2025-09-30
Journal Articles
- WDFY4 Is Required for Cross-Presentation in Response to Viral and Tumor AntigensHerbert W Virgin, Kenneth M Murphy, William E Gillanders, Wayne Yokoyama, Science Magazine
Press Mentions
Two WashU Medicine Projects Compete in STAT Madness TournamentMarch 6th, 2025- Neoantigen DNA Vaccine for Triple-Negative Breast Cancer Shows High Survival RatesNovember 15th, 2024
- Vaccines Become Breakthrough in Preventing Breast CancerNovember 15th, 2024
Grant Support
- Surgical Oncology Basic Science and Translational Research Training ProgramWASHINGTON UNIVERSITY1988–2029
- Targeting Neoantigens in Triple Negative Breast CancerWASHINGTON UNIVERSITY2019–2025
- Peripheral Blood Molecular Staging Of Breast CancerNational Cancer Institute2006–2010
- Molecular Detection Of Breast Cancer In Peripheral BloodNational Cancer Institute2004–2006
- Molecular Detection Of Breast Cancer In Peripheral BloodNational Cancer Institute2002–2004
Professional Memberships
- Member
- Member
- American Association of Endocrine SurgeonsMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
